EP1315512A4 - Zielgerichtetes einbringen mit hilfe von adenoviren und adenovirale manipulationder immunsystemantwort unter verwendung von zielgerichteten peptiden - Google Patents

Zielgerichtetes einbringen mit hilfe von adenoviren und adenovirale manipulationder immunsystemantwort unter verwendung von zielgerichteten peptiden

Info

Publication number
EP1315512A4
EP1315512A4 EP01970682A EP01970682A EP1315512A4 EP 1315512 A4 EP1315512 A4 EP 1315512A4 EP 01970682 A EP01970682 A EP 01970682A EP 01970682 A EP01970682 A EP 01970682A EP 1315512 A4 EP1315512 A4 EP 1315512A4
Authority
EP
European Patent Office
Prior art keywords
disclosed
targeting
peptides
novel
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01970682A
Other languages
English (en)
French (fr)
Other versions
EP1315512A2 (de
Inventor
Wadih Arap
Renata Pasqualini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
The University of Texas at Austin
Original Assignee
The University of Texas System
The University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System, The University of Texas at Austin filed Critical The University of Texas System
Publication of EP1315512A2 publication Critical patent/EP1315512A2/de
Publication of EP1315512A4 publication Critical patent/EP1315512A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Wood Science & Technology (AREA)
  • Child & Adolescent Psychology (AREA)
EP01970682A 2000-09-08 2001-09-07 Zielgerichtetes einbringen mit hilfe von adenoviren und adenovirale manipulationder immunsystemantwort unter verwendung von zielgerichteten peptiden Withdrawn EP1315512A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23126600P 2000-09-08 2000-09-08
US231266P 2000-09-08
US76510101A 2001-01-17 2001-01-17
US765101 2001-01-17
PCT/US2001/028045 WO2002020724A2 (en) 2000-09-08 2001-09-07 Adenoviral targeting and manipulation of immune system response using targeting peptides

Publications (2)

Publication Number Publication Date
EP1315512A2 EP1315512A2 (de) 2003-06-04
EP1315512A4 true EP1315512A4 (de) 2005-11-09

Family

ID=26924954

Family Applications (6)

Application Number Title Priority Date Filing Date
EP01968683A Withdrawn EP1315840A4 (de) 2000-09-08 2001-09-07 Biopanning und schnelle analyse von selektiven interaktiven liganden
EP01968603A Expired - Lifetime EP1322755B1 (de) 2000-09-08 2001-09-07 Durch phagendisplay identifizierte zielpeptide des menschen und der maus
EP01970681A Withdrawn EP1315830A4 (de) 2000-09-08 2001-09-07 Zusammensetzungen und verfahren zur zielgerichteten, in vivo einbringung von peptiden in den menschen
EP01970671A Withdrawn EP1315965A4 (de) 2000-09-08 2001-09-07 Verfahren und zusammensetzungen für "targeting" in vitro
EP08016646A Withdrawn EP2028187A1 (de) 2000-09-08 2001-09-07 Durch Phagenanzeigen identifizierte, auf Menschen und Mäuse abgezielte Peptide
EP01970682A Withdrawn EP1315512A4 (de) 2000-09-08 2001-09-07 Zielgerichtetes einbringen mit hilfe von adenoviren und adenovirale manipulationder immunsystemantwort unter verwendung von zielgerichteten peptiden

Family Applications Before (5)

Application Number Title Priority Date Filing Date
EP01968683A Withdrawn EP1315840A4 (de) 2000-09-08 2001-09-07 Biopanning und schnelle analyse von selektiven interaktiven liganden
EP01968603A Expired - Lifetime EP1322755B1 (de) 2000-09-08 2001-09-07 Durch phagendisplay identifizierte zielpeptide des menschen und der maus
EP01970681A Withdrawn EP1315830A4 (de) 2000-09-08 2001-09-07 Zusammensetzungen und verfahren zur zielgerichteten, in vivo einbringung von peptiden in den menschen
EP01970671A Withdrawn EP1315965A4 (de) 2000-09-08 2001-09-07 Verfahren und zusammensetzungen für "targeting" in vitro
EP08016646A Withdrawn EP2028187A1 (de) 2000-09-08 2001-09-07 Durch Phagenanzeigen identifizierte, auf Menschen und Mäuse abgezielte Peptide

Country Status (7)

Country Link
EP (6) EP1315840A4 (de)
JP (6) JP2004536020A (de)
AT (1) ATE478141T1 (de)
CA (5) CA2421271A1 (de)
DE (1) DE60142840D1 (de)
PT (1) PT1322755E (de)
WO (4) WO2002020722A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE407943T1 (de) * 1998-03-13 2008-09-15 Burnham Inst Zielsuchende verbindungen für verschiedene organe und gewebe
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
AU2001288914A1 (en) * 2000-09-08 2002-03-22 Board Of Regents, The University Of Texas System Biopanning and rapid analysis of selective interactive ligands (brasil)
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US8507445B2 (en) 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
AU2003215280A1 (en) 2002-02-15 2003-09-09 Northwestern University Self-assembly of peptide-amphiphile nanofibers under physiological conditions
EP1346729A1 (de) * 2002-03-19 2003-09-24 Cardiovascular Research Institute Maastricht Zielgerichtete Therapie der myokardialen Angiogenese durch CD13/APN
US9321992B2 (en) 2002-06-14 2016-04-26 Case Western Reserve University Cell targeting methods and compositions
EP1546714A4 (de) * 2002-08-30 2007-12-05 Univ Texas Zusammensetzungen und verfahren zur verwendung beim abzielen auf peptide zur diagnose und therapie von krebs im menschen
US7554021B2 (en) 2002-11-12 2009-06-30 Northwestern University Composition and method for self-assembly and mineralization of peptide amphiphiles
WO2004084950A2 (en) * 2003-03-24 2004-10-07 Case Western Reserve University Cell targeting methods and compositions
US8709998B2 (en) * 2003-04-22 2014-04-29 Ipsen Pharma S.A.S. Peptide vectors
US20040248109A1 (en) * 2003-06-09 2004-12-09 Lawrence Greenfield Methods for selecting protein binding moieties
WO2005026195A1 (en) * 2003-09-12 2005-03-24 Board Of Regents, The University Of Texas System Biopanning as an approach to study the pathogenesis of and produce novel treatment modalities for invasive aspergillosis
JP4870348B2 (ja) * 2003-12-04 2012-02-08 株式会社ペルセウスプロテオミクス 細胞表面抗原に対する抗体取得とその抗原同定
JP2011239784A (ja) * 2003-12-04 2011-12-01 Perseus Proteomics Inc 細胞表面抗原に対する抗体取得とその抗原同定
KR20070004560A (ko) 2003-12-05 2007-01-09 노오쓰웨스턴 유니버시티 성장 인자 전달을 위한 자가조립 펩티드 친양매성 화합물들및 관련 방법들
US8377484B1 (en) * 2004-05-06 2013-02-19 Maria V. Tsiper Tumor encapsulation for prevention and treatment of metastatic cancer disease
CN1294418C (zh) * 2004-08-09 2007-01-10 中国人民解放军南京军区南京总医院 检测白念珠菌菌丝蛋白抗体的方法及试剂盒
GB0422431D0 (en) * 2004-10-08 2004-11-10 Affitech As Method
ITRM20040568A1 (it) * 2004-11-18 2005-02-18 Uni Degli Studi Di Roma Tor Vergata Uso della tecnica "phage display" per l'identificazione di peptidi con capacita' di legame a cellule staminali/progenitore, peptidi cosi' ottenuti e loro usi.
WO2006114478A1 (en) * 2005-04-26 2006-11-02 Karyon-Ctt Ltd Diagnostic and therapeutic agents
JP5173838B2 (ja) 2006-02-13 2013-04-03 アレシア・バイオセラピューティクス・インコーポレーテッド 骨リモデリングのプロセスと関係があるポリヌクレオチドおよびポリペプチド配列
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
JP5167155B2 (ja) * 2006-03-09 2013-03-21 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ペプチド結合に基づく多数の細胞株のプロファイリングに関連した組成物および方法
AU2008219972A1 (en) * 2007-02-27 2008-09-04 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-GRP78 antibody as active ingredient
US8076295B2 (en) 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
US7807630B2 (en) * 2007-09-14 2010-10-05 Vanderbilt University Targeting of Notch3 receptor function for cancer therapy
EP3543256A1 (de) * 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modifizierte antikörperzusammensetzungen, verfahren zur herstellung und verwendung davon
EP2419116A1 (de) 2009-04-13 2012-02-22 North Western University Neue peptidbasierte gerüste für knorpelregenerierung und anwendungsverfahren dafür
CA2827029C (en) 2011-02-11 2019-07-02 The Regents Of The University Of Michigan Tripeptide compositions and methods
WO2013116903A1 (en) * 2012-02-10 2013-08-15 Phylogica Limited Methods for the characterisation of interaction sites on target proteins
WO2013149237A1 (en) * 2012-03-30 2013-10-03 Board Of Regents, The University Of Texas System Targeting intracellular organelle zip codes with functional homing ligands from cell-internalizing phage combinatorial libraries
AU2013293062A1 (en) 2012-07-19 2014-07-24 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
GB201308745D0 (en) * 2013-05-15 2013-06-26 Imp Innovations Bacteriophage
CN103497236B (zh) * 2013-09-25 2017-05-10 浙江省医学科学院 靶向wisp‑1蛋白的特异性七肽及其应用
GB2522412A (en) * 2014-01-22 2015-07-29 Agency Science Tech & Res Antimicrobial peptidomimetics
MX367600B (es) 2014-02-19 2019-08-28 Hoffmann La Roche Transportador de la barrera hematoencefálica.
JP6705755B2 (ja) * 2014-05-19 2020-06-03 バロ セラピューティクス オイＶａｌｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｏｙ 癌ワクチン開発のための改変アデノウイルス
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN105769909A (zh) * 2016-05-13 2016-07-20 云南舜喜再生医学工程有限公司 一种直接获得富含细胞因子血清的采血器及方法
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
KR101921836B1 (ko) 2017-11-23 2018-11-26 서울대학교병원 피부성체 줄기세포의 분화 조절 방법, 및 피부성체 줄기세포의 분화 조절용 조성물 및 키트
JP2022502494A (ja) * 2018-09-25 2022-01-11 エモリー ユニバーシティー 細胞認識およびインテグレーションのための核酸
CN109137086A (zh) * 2018-10-16 2019-01-04 梁耀极 一种改良的全长mRNA测序的建库方法
BR102019014302A2 (pt) 2019-07-10 2021-12-28 Universidade Federal de Uberlândia Peptídeos recombinantes ligantes ao anticorpo tumoral específico para cancer de mama e uso
EP3767628B1 (de) 2019-07-18 2024-03-27 Bayer Aktiengesellschaft Selektion von antikörpern / antikörperfragmenten
US20230357373A1 (en) * 2019-12-17 2023-11-09 Mie University Methods and compositions for evaluating and treating fibrosis
KR102749110B1 (ko) * 2021-11-04 2025-01-03 (주)케어젠 생리 활성을 갖는 펩타이드 및 그의 용도
GB202211043D0 (en) * 2022-07-28 2022-09-14 Univ Birmingham Peptide agonist
TW202620035A (zh) * 2024-08-30 2026-05-16 日商三井化學股份有限公司 癌症標靶胜肽、輸送載體、及醫藥組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046284A2 (en) * 1998-03-13 1999-09-16 The Burnham Institute Molecules that home to various selected organs or tissues

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US5206347A (en) 1985-08-06 1993-04-27 La Jolla Cancer Research Foundation Isolation and use of receptors binding to a peptide column
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5252296A (en) 1990-05-15 1993-10-12 Chiron Corporation Method and apparatus for biopolymer synthesis
JP3407072B2 (ja) 1991-02-14 2003-05-19 バクスター、インターナショナル、インコーポレイテッド リポソームへの認識物質の結合
US5603872A (en) 1991-02-14 1997-02-18 Baxter International Inc. Method of binding recognizing substances to liposomes
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
AU684510B2 (en) * 1993-05-28 1997-12-18 Chiron Corporation Method for selection of biologically active peptide sequences
US5492807A (en) 1993-11-19 1996-02-20 Santi; Daniel V. Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease
US5622699A (en) 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
US6068829A (en) 1995-09-11 2000-05-30 The Burnham Institute Method of identifying molecules that home to a selected organ in vivo
AU693723B2 (en) * 1995-09-11 1998-07-02 La Jolla Cancer Research Foundation Molecules that home to a selected organ or tissue in vivo and methods of identifying same
EP1109897A1 (de) * 1998-09-07 2001-06-27 Eberhard-Karls-Universität Tübingen Universitätsklinikum Verfahren zur selektion von peptiden für zielgerichteten pharma- und markertransport und peptide damit entdeckt

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046284A2 (en) * 1998-03-13 1999-09-16 The Burnham Institute Molecules that home to various selected organs or tissues

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARAP W ET AL: "CANCER TREATMENT BY TARGETED DRUG DELIVERY TO TUMOR VASCULATURE IN A MOUSE MODEL", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 279, 16 January 1998 (1998-01-16), pages 377 - 380, XP000857470, ISSN: 0036-8075 *
ELLERBY H M ET AL: "ANTI-CANCER ACTIVITY OF TARGETED PRO-APOPTOTIC PEPTIDES", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 5, no. 9, September 1999 (1999-09-01), pages 1032 - 1038, XP000995556, ISSN: 1078-8956 *
RAJOTTE D ET AL: "MEMBRANE DIPEPTIDASE IS THE RECEPTOR FOR A LUNG-TARGETING PEPTIDE IDENTIFIED BY IN VIVO PHAGE DISPLAY", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 17, 23 April 1999 (1999-04-23), pages 11593 - 11598, XP000869582, ISSN: 0021-9258 *
WANG H ET AL: "Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 18 JAN 2000, vol. 97, no. 2, 18 January 2000 (2000-01-18), pages 847 - 852, XP001206541, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
JP5591209B2 (ja) 2014-09-17
WO2002020722A3 (en) 2003-02-06
WO2002020724A2 (en) 2002-03-14
EP1315965A4 (de) 2006-04-05
WO2002020822A2 (en) 2002-03-14
JP2004515751A (ja) 2004-05-27
EP1322755A4 (de) 2006-04-05
CA2421191A1 (en) 2002-03-14
EP1315512A2 (de) 2003-06-04
CA2421271A1 (en) 2002-03-14
DE60142840D1 (de) 2010-09-30
JP2004530404A (ja) 2004-10-07
ATE478141T1 (de) 2010-09-15
PT1322755E (pt) 2010-11-19
CA2421200A1 (en) 2002-03-14
WO2002020722A9 (en) 2003-08-21
WO2002020723A2 (en) 2002-03-14
JP2012065662A (ja) 2012-04-05
EP1315840A4 (de) 2005-11-02
EP1315965A2 (de) 2003-06-04
WO2002020822A3 (en) 2002-06-27
JP2004536020A (ja) 2004-12-02
EP1322755A1 (de) 2003-07-02
EP1315840A2 (de) 2003-06-04
JP2011120587A (ja) 2011-06-23
WO2002020722A2 (en) 2002-03-14
JP2004533803A (ja) 2004-11-11
EP1322755B1 (de) 2010-08-18
CA2421380A1 (en) 2002-03-14
CA2421195A1 (en) 2002-03-14
EP2028187A1 (de) 2009-02-25
EP1315830A2 (de) 2003-06-04
EP1315830A4 (de) 2005-10-19
WO2002020723A3 (en) 2002-08-29
WO2002020724A3 (en) 2002-07-11

Similar Documents

Publication Publication Date Title
EP1322755A4 (de) Durch phagendisplay identifizierte zielgene des menschen und der maus
Bausero et al. Surface expression of Hsp25 and Hsp72 differentially regulates tumor growth and metastasis
DE69922933D1 (de) Anwendungen für humane nicht autologe, mesenchymale stammzellen
BR0211474A (pt) Uso de tat de hiv-1 biologicamente ativa, fragmentos ou derivadas desta, para atingir e/ou ativar células apresentadoras de antìgeno, e/ou para disponibilizar moléculas carga para vacinação e/ou tratamento preventivo ou terapêutico de outras doenças
AU688101B2 (en) Live vaccine for the treatment of tumour diseases
EA200401506A1 (ru) Рекомбинантный поксвирус, экспрессирующий гомологичные гены, встроенные в поксвирусный геном
CY1107351T1 (el) Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης
ES2107041T3 (es) Variantes de activador de plasminogeno tisular obtenidos por glicosilacion, que presentan propiedades terapeuticas.
ATE336267T1 (de) Auf lipiden basierendes system zur zielgerichteten verabreichung diagnostischer wirkstoffe
DE60018920D1 (de) Rekombinante adenovirale vektoren, die chimäre fiberproteine exprimieren, für die zellspezifische infektion und genomische integration
ATE218879T1 (de) Therapeutische verwendungen von bakterizide/permeabilitätserhöhende protein dimer produkte
ATE287958T1 (de) Verbesserte krebstherapie
ATE423574T1 (de) Dominant-negativer plb mutant zur behandlung der herzerkrankungen
ES2439954T3 (es) Vectores víricos recombinantes para la prevención y la protección contra la infección por alfavirus
DE60129069D1 (de) Hepatitis B Virus Vektoren für Gentherapie
ATE364315T1 (de) Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung
WO2003092598A3 (en) Treatment for pompe disease
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
ATE371737T1 (de) Proteaseresistente flint-analoge
ATE239749T1 (de) Phosphor-enthaltende dendrimere als transfektionsagente
ATE210990T1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt
HK1044568A1 (zh) 一种治疗剂的应激应答性诱导及其使用方法
MX9708615A (es) Terapia de genes animales.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030307

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PASQUALINI, RENATA

Inventor name: ARAP, WADIH

A4 Supplementary search report drawn up and despatched

Effective date: 20050923

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051217

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PASQUALINI, RENATA

Inventor name: ARAP, WADIH